Abstract

Emerging SARS-CoV-2 variants raise questions about escape from previous immunity. As the population immunity to SARS-CoV-2 has become more complex due to prior infections with different variants, vaccinations or the combination of both, understanding the antigenic relationship between variants is needed. Here, we have assessed neutralizing capacity of 120 blood specimens from convalescent individuals infected with ancestral SARS-CoV-2, Alpha, Beta, Gamma or Delta, double vaccinated individuals and patients after breakthrough infections with Delta or Omicron-BA.1. Neutralization against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta and Omicron-BA.1) determined by plaque-reduction neutralization assay allowed us to map the antigenic relationship of SARS-CoV-2 variants. Highest neutralization titers were observed against the homologous variant. Antigenic cartography identified Zeta and Omicron-BA.1 as separate antigenic clusters. Substantial immune escape in vaccinated individuals was detected for Omicron-BA.1 but not Zeta. Combined infection/vaccination derived immunity results in less Omicron-BA.1 immune escape. Last, breakthrough infections with Omicron-BA.1 lead to broadly neutralizing sera.

Emerging SARS-CoV-2 variants raise concerns on protective immunity. Here the authors show that convalescent sera from people infected with Alpha, Beta, Gamma or Delta show a significant drop of Omicron-BA.1 neutralization and that vaccine-breakthrough infections with Omicron-BA.1 or Delta result in robust neutralization for both Delta and Omicron-BA.1.

Details

Title
Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
Author
Bekliz, Meriem 1   VIAFID ORCID Logo  ; Adea, Kenneth 1 ; Vetter, Pauline 2 ; Eberhardt, Christiane S. 3 ; Hosszu-Fellous, Krisztina 2 ; Vu, Diem-Lan 4 ; Puhach, Olha 1   VIAFID ORCID Logo  ; Essaidi-Laziosi, Manel 1 ; Waldvogel-Abramowski, Sophie 5 ; Stephan, Caroline 5 ; L’Huillier, Arnaud G. 6 ; Siegrist, Claire-Anne 7   VIAFID ORCID Logo  ; Didierlaurent, Arnaud M. 7 ; Kaiser, Laurent 2   VIAFID ORCID Logo  ; Meyer, Benjamin 7   VIAFID ORCID Logo  ; Eckerle, Isabella 8   VIAFID ORCID Logo 

 University of Geneva, Department of Microbiology and Molecular Medicine, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988) 
 Geneva University Hospitals, Division of Infectious Diseases, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812); Geneva University Hospitals and Faculty of Medicine, Geneva Centre for Emerging Viral Diseases, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
 University of Geneva, Center for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988); University of Geneva, Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988); Geneva University Hospitals, Center for Vaccinology, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
 Geneva University Hospitals, Division of Infectious Diseases, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
 Geneva University Hospitals, Transfusion Unit, Department of Medicine, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
 Geneva University Hospitals and Faculty of Medicine, Pediatric Infectious Diseases Unit, Department of Women, Child and Adolescent Medicine, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
 University of Geneva, Center for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988) 
 University of Geneva, Department of Microbiology and Molecular Medicine, Geneva, Switzerland (GRID:grid.8591.5) (ISNI:0000 0001 2322 4988); Geneva University Hospitals, Division of Infectious Diseases, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812); Geneva University Hospitals and Faculty of Medicine, Geneva Centre for Emerging Viral Diseases, Geneva, Switzerland (GRID:grid.150338.c) (ISNI:0000 0001 0721 9812) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2684300401
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.